Ortho Derm Turns To Cash-Pay Model To Address Prior Authorization Hurdles
With dermatologists reporting issues with prior authorization requirements, Ortho Derm is offering several reduced-price products under a new cash-pay format.
You may also be interested in...
Keeping Track: Novel Approvals For Diacomit, Takhzyro And Oxervate; CRLs For Mallinckrodt And Allergan
The latest drug development news and highlights from our US FDA Performance Tracker.
Valeant will change its name to Bausch Health beginning in July and get a new ticker symbol, BHC, as the new management team looks to leave the company's checkered past behind.
Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.